- Email: [email protected]
P-802 Metastatic carcinoma in the mediastinum from unknown primary site and its radiotherapeutic palliation
$330
Posters/Supportive and palliative care/Oncology nursing
Iong~erm efficacy of biological pleuredes~s induction using the thoracoscopic powder collagen insufflafion Methods: 4,5 patients with malignant pleural effusions and expected survival of >1 month received thoraeoscopic collagen insufflation (1 g) under general anesthesia Patients were bllowed up in 1.3.6 and 12 months after pleurodesis induction Results: The procedures were well tolerated and no significant adverse effects were observed There were no serious complications or deaths The full dlsappearanca of ploural fluid after operations was aciloved In all cases. In 30 days 43 of 45 patients (0.95) showed a complete response to the biological pleuredes~s induction, in 160 days the pos~]ve effect was observed in 23 of 27 survived patients (0.85). In 40 of 45 patients (0.69) relapses of pleural fluid accumulation were not registered for the whole porlod of follow ub. they old not require addiUonal intervention. Conclusions: Powder collagen insufflation in pleural cavity is a simple and effecUve method of biological pleumdesis indu~on for patients with malignant pleural effusions [~T
Metastatic ¢ardnorna In the medlastlnum from unknown prlrnary sits and Its radlotherapeUtlc palliation
F. Amoil. G. Mills. K.R. Murty. G. Burton. Lo~stana State Untversrty Hea/~
Scten~s Center, Shreveport Lous~ana, USA Background: Unlike mediast]nal metastasis I~om lung cancer, metastatic ca~noma in the mediastinum from ur~nown primary site (MCMJJPS) is relatively uncommon. MCMJJPS can acoount for the occurrenco of superior vena eaval obstru~on, respiratory distress, dysphagia, obstru~va atalectasis. and secondary neurolngieal complications This study raviows cur esperience with palliative treatment of patients with MCM~IPS Methods: A retrospective raviow of the radiation oncelogy database identified 11 individuals who had bean treated by radiation ~ r palliation of MCM-UPS during a 21-year period Their patient records were esaminad to document clinical features, affects of treatment, and survival Results: The mean age was 55 years; only 18% of the subjects were elderly (~>65 years). Adenocaranoma was the most common metastatic tumor histology. The more often observed manifestations of MCM UPS included dyspnea and suberlor vena caval obstruot]on (facial. neck and upper limb swelling). Among the evaluable symptomatic incJvlduals, subJeot]ve palliation was aciloved in 60% of the cases. The objective response (i.e.. complete resolution of signs of subenor vena caval obstruction or associated supraclavicular metastatic tumor) rate was appm~dmately ,50% An applied radiation dose of ~>30Gy produced twice as many respondem to treatment as one of <30 Gy (67% and 33% respectively) The median survival was 3 months, and the 2-year crude survival rate was 18% Conclusion: Though the results of radiotherapy in individuals with MCMUPS is poorly documented and irradiation may be deemed appropriate in most symptomatic cases, the present esberience suggests that radiotherapy deserves consideration as a first choice when a management plan for palliation of this particular neoplesUc maladie is developed.
support with cJfferent schedules are warranted. Tils investigator inflated ~al recoJved research funding from Amgen [P~lThe
national lung cancer forum for numss webslts
J Baker L/andough Hospita/, Cardff,, Wa/es, United l~ngdorn InlToductlon The National Lung Cancer Forum for Nurses (NLCFN) wobsite wllch was launched in April 2002 was the first cancar website for both prolioss~onals and patients run by nurses. The aim was: To enhance networking opportunities and to disseminate information and research for membem. To provide up~o date information on lung cancar t]-eatment options and subport services for patients and careers. The Website provides a unique means of information provision for lung cancer pahhents, caters and professionals It also allows NLCFN members to log in to receive information about the Forum's act ivi'des . download articles and newsletters and share ideas with each other via the message heard The Webslte: The website was developed by CarcJff-besed web development company. Sequence FuncJng was provided by Astra Zenece and Sequence The website contains: About Us an introductory page detailing the aotiv~]es and objectives of the NLCFN; clinical, developmental, educeUonal and profasslonal Regional Groups dynamic map with inlbrmation about regional support groubs for both patients and professionals News latest articles and information published by the NLCFN Events information about study days and conferences Resources pre~des a wealth of links to related s~tes on the Interest Contact Us - register of committee members Education - relevant courses and educational pregrammea John Loyden Award - this was set up by the family in memory of a lung cancer patient to raise and provide funds for inoovafive projects for the benefit of lung cancer patients Project - allows members to post current projects, share e~perieneas, invite discussion and collaboration Forum a message board where members are able to ask and answer qoost]ons Additional lioatures include anows ticker on the front page of the site with 'clJckable' headlines and download facilities for questionnaires, newsletters and more. There is a continuing increase in the number of people accessing the s~tefrom all over the wodd. There are over 200 registered members who access the pro~ssioeal side of the site. some of which are international members from Australia and the United States On average the site gets about 50 i'tts per day and the average length of visit is about 1,5 minutes There is a high percentage of returning visitors The site links to other related web sites and there are reciprocal arrangements ~ r them to link to our site Since Its inception, we have operated a policy of continuing improvement in order to offer more services to cur members and patients alike
~Supportlve care w l ~ pegfllgrasUm Improves neut~openlc endpolnts In paUants receiving dose dense ctlemotherapy
~Lung
Cancer In Wales - The development of a National Forum
C Andrews. J Garst. F Dunphy. S Blackwall. K Young. T BjurstTem. J Crawford Duke University Mscical Center, Durham, Nor~ Catalina, USA
tOngdom, 2Royal Gwent Hospital, Newport, UK, Newport, UK 3Hotme Towers, Mane Curie Hospt~, Cerddf, UK
Purpose: One of the roles of the clinical research nurse Is to assess paUent adverse events and the need for dose modJficaUons or delays duneg chemotherapy t]'eatment. A common adverse event causing t]'eatment modification and delay Is neutropenJa. Pegfdgrest]m Is approved to accelerate white blood cell recovery and therefore prevent neut]'ogenJa. Through this supportive care measure paUents are able to recoive scheduled full dose chemotherapy. A phase 2 tnal was conducted to evaluate the Jmpaot of Pagflgrasfim when given with dose dense chemotherapy in patients with thoracic malignancies Desc=rlptlon: In this 1Tial. stage 3B and 4 non-small cell lung cancer patients ware dosed for bur 21 day cycles with Carbpplatin h,UC 6 on day land VinorelbJne 30 mg/m ~ on days 1 and 6. Pegfilgrest]m 6 mg was given on day 9 of each cycle. The primary endpoJnt was the Jnadence of febnle neulzopenJa In cycle 1. Secondary endpoJnts were the number of grade 3/4 neut]'ppenJc events, thmmbocytepenia, and non~amatologie tmdcifiea across all cycles Results: Thirty patients were enrolled to this study Tha patiants included 21 males and g females with PSi<2. mecian age 61. median baseline hemogiebin 12 3. meclan besaline platelat count 267. and median pasalina absolute nautTophil count 5 4 Overall. nine chamotharapy dose raductJons and 2 ~noralbine dose omissions were related to nautrepenia Thare wera two incidences of febrile neutropenia, only one of these occurred in cycle 1 With the supportive care use of Pegfdgrast]m. eleven episodes of neulzopenia occurred prior to day 9 Pegfilgrastim dose (grade 1/2 = 8. grade 3/4 = 3). No treatment delays were related to ncutrepenla. Conclusions: Supportive care use of Pegfilgrast]m on day 9 provided pretect]on against neulzppenJc adverse events. Further stucies of Pegflgrast]m
Wales has a population of 2 6 million, with a higher incidence and mortality from lung cencar than England There also appear to be inequalities in survival within Wales In addi'don, resources have been less available ~r c:~qcer services in Wales in comparison with England An All Wales Lung Cancer Forum was established in September 2000 to improve care for patients by providing health pro~ssioeals with support. education and an opportunity ~ r networking There is a particular emphasis on shanng research, development and innovative practice. The forum is a focus Ibr increasing awareness of the problem and aims to provide a national vc~co on strategic issues in lung cancer. Membership Is open to all health care prefesslonals who have an Interest In caring for people with lung cancer. The forum is run by a steenng commutes of speaalist nurses whose responsibilities are to: - Lead the development of policy for lung cancer nursing in Wales - Organise an annual coherence - Publish a twice yearly newsletter - Link with the National Lung Cancer Forum for Nurses (UK0 - Provide a resource and a voice for lung cancer care in Wales Achievements so far include: - A strong interdisaplinary membemhip of more than 150 professionals wftch has grown year on year. Five succassful conliorences. Publication and cistnbut]on of eight nowstetters Linking and working with the Na'donal Lung Cancer Forum for Nurses (UK) on Identified pnonUes and developments.
J Baker~ G Tapper2. A Wilson ~ IL/andough Hospital, Cardiff, United
Posters/Supportive and palliative care/Oncology nursing
Iong~erm efficacy of biological pleuredes~s induction using the thoracoscopic powder collagen insufflafion Methods: 4,5 patients with malignant pleural effusions and expected survival of >1 month received thoraeoscopic collagen insufflation (1 g) under general anesthesia Patients were bllowed up in 1.3.6 and 12 months after pleurodesis induction Results: The procedures were well tolerated and no significant adverse effects were observed There were no serious complications or deaths The full dlsappearanca of ploural fluid after operations was aciloved In all cases. In 30 days 43 of 45 patients (0.95) showed a complete response to the biological pleuredes~s induction, in 160 days the pos~]ve effect was observed in 23 of 27 survived patients (0.85). In 40 of 45 patients (0.69) relapses of pleural fluid accumulation were not registered for the whole porlod of follow ub. they old not require addiUonal intervention. Conclusions: Powder collagen insufflation in pleural cavity is a simple and effecUve method of biological pleumdesis indu~on for patients with malignant pleural effusions [~T
Metastatic ¢ardnorna In the medlastlnum from unknown prlrnary sits and Its radlotherapeUtlc palliation
F. Amoil. G. Mills. K.R. Murty. G. Burton. Lo~stana State Untversrty Hea/~
Scten~s Center, Shreveport Lous~ana, USA Background: Unlike mediast]nal metastasis I~om lung cancer, metastatic ca~noma in the mediastinum from ur~nown primary site (MCMJJPS) is relatively uncommon. MCMJJPS can acoount for the occurrenco of superior vena eaval obstru~on, respiratory distress, dysphagia, obstru~va atalectasis. and secondary neurolngieal complications This study raviows cur esperience with palliative treatment of patients with MCM~IPS Methods: A retrospective raviow of the radiation oncelogy database identified 11 individuals who had bean treated by radiation ~ r palliation of MCM-UPS during a 21-year period Their patient records were esaminad to document clinical features, affects of treatment, and survival Results: The mean age was 55 years; only 18% of the subjects were elderly (~>65 years). Adenocaranoma was the most common metastatic tumor histology. The more often observed manifestations of MCM UPS included dyspnea and suberlor vena caval obstruot]on (facial. neck and upper limb swelling). Among the evaluable symptomatic incJvlduals, subJeot]ve palliation was aciloved in 60% of the cases. The objective response (i.e.. complete resolution of signs of subenor vena caval obstruction or associated supraclavicular metastatic tumor) rate was appm~dmately ,50% An applied radiation dose of ~>30Gy produced twice as many respondem to treatment as one of <30 Gy (67% and 33% respectively) The median survival was 3 months, and the 2-year crude survival rate was 18% Conclusion: Though the results of radiotherapy in individuals with MCMUPS is poorly documented and irradiation may be deemed appropriate in most symptomatic cases, the present esberience suggests that radiotherapy deserves consideration as a first choice when a management plan for palliation of this particular neoplesUc maladie is developed.
support with cJfferent schedules are warranted. Tils investigator inflated ~al recoJved research funding from Amgen [P~lThe
national lung cancer forum for numss webslts
J Baker L/andough Hospita/, Cardff,, Wa/es, United l~ngdorn InlToductlon The National Lung Cancer Forum for Nurses (NLCFN) wobsite wllch was launched in April 2002 was the first cancar website for both prolioss~onals and patients run by nurses. The aim was: To enhance networking opportunities and to disseminate information and research for membem. To provide up~o date information on lung cancar t]-eatment options and subport services for patients and careers. The Website provides a unique means of information provision for lung cancer pahhents, caters and professionals It also allows NLCFN members to log in to receive information about the Forum's act ivi'des . download articles and newsletters and share ideas with each other via the message heard The Webslte: The website was developed by CarcJff-besed web development company. Sequence FuncJng was provided by Astra Zenece and Sequence The website contains: About Us an introductory page detailing the aotiv~]es and objectives of the NLCFN; clinical, developmental, educeUonal and profasslonal Regional Groups dynamic map with inlbrmation about regional support groubs for both patients and professionals News latest articles and information published by the NLCFN Events information about study days and conferences Resources pre~des a wealth of links to related s~tes on the Interest Contact Us - register of committee members Education - relevant courses and educational pregrammea John Loyden Award - this was set up by the family in memory of a lung cancer patient to raise and provide funds for inoovafive projects for the benefit of lung cancer patients Project - allows members to post current projects, share e~perieneas, invite discussion and collaboration Forum a message board where members are able to ask and answer qoost]ons Additional lioatures include anows ticker on the front page of the site with 'clJckable' headlines and download facilities for questionnaires, newsletters and more. There is a continuing increase in the number of people accessing the s~tefrom all over the wodd. There are over 200 registered members who access the pro~ssioeal side of the site. some of which are international members from Australia and the United States On average the site gets about 50 i'tts per day and the average length of visit is about 1,5 minutes There is a high percentage of returning visitors The site links to other related web sites and there are reciprocal arrangements ~ r them to link to our site Since Its inception, we have operated a policy of continuing improvement in order to offer more services to cur members and patients alike
~Supportlve care w l ~ pegfllgrasUm Improves neut~openlc endpolnts In paUants receiving dose dense ctlemotherapy
~Lung
Cancer In Wales - The development of a National Forum
C Andrews. J Garst. F Dunphy. S Blackwall. K Young. T BjurstTem. J Crawford Duke University Mscical Center, Durham, Nor~ Catalina, USA
tOngdom, 2Royal Gwent Hospital, Newport, UK, Newport, UK 3Hotme Towers, Mane Curie Hospt~, Cerddf, UK
Purpose: One of the roles of the clinical research nurse Is to assess paUent adverse events and the need for dose modJficaUons or delays duneg chemotherapy t]'eatment. A common adverse event causing t]'eatment modification and delay Is neutropenJa. Pegfdgrest]m Is approved to accelerate white blood cell recovery and therefore prevent neut]'ogenJa. Through this supportive care measure paUents are able to recoive scheduled full dose chemotherapy. A phase 2 tnal was conducted to evaluate the Jmpaot of Pagflgrasfim when given with dose dense chemotherapy in patients with thoracic malignancies Desc=rlptlon: In this 1Tial. stage 3B and 4 non-small cell lung cancer patients ware dosed for bur 21 day cycles with Carbpplatin h,UC 6 on day land VinorelbJne 30 mg/m ~ on days 1 and 6. Pegfilgrest]m 6 mg was given on day 9 of each cycle. The primary endpoJnt was the Jnadence of febnle neulzopenJa In cycle 1. Secondary endpoJnts were the number of grade 3/4 neut]'ppenJc events, thmmbocytepenia, and non~amatologie tmdcifiea across all cycles Results: Thirty patients were enrolled to this study Tha patiants included 21 males and g females with PSi<2. mecian age 61. median baseline hemogiebin 12 3. meclan besaline platelat count 267. and median pasalina absolute nautTophil count 5 4 Overall. nine chamotharapy dose raductJons and 2 ~noralbine dose omissions were related to nautrepenia Thare wera two incidences of febrile neutropenia, only one of these occurred in cycle 1 With the supportive care use of Pegfdgrast]m. eleven episodes of neulzopenia occurred prior to day 9 Pegfilgrastim dose (grade 1/2 = 8. grade 3/4 = 3). No treatment delays were related to ncutrepenla. Conclusions: Supportive care use of Pegfilgrast]m on day 9 provided pretect]on against neulzppenJc adverse events. Further stucies of Pegflgrast]m
Wales has a population of 2 6 million, with a higher incidence and mortality from lung cencar than England There also appear to be inequalities in survival within Wales In addi'don, resources have been less available ~r c:~qcer services in Wales in comparison with England An All Wales Lung Cancer Forum was established in September 2000 to improve care for patients by providing health pro~ssioeals with support. education and an opportunity ~ r networking There is a particular emphasis on shanng research, development and innovative practice. The forum is a focus Ibr increasing awareness of the problem and aims to provide a national vc~co on strategic issues in lung cancer. Membership Is open to all health care prefesslonals who have an Interest In caring for people with lung cancer. The forum is run by a steenng commutes of speaalist nurses whose responsibilities are to: - Lead the development of policy for lung cancer nursing in Wales - Organise an annual coherence - Publish a twice yearly newsletter - Link with the National Lung Cancer Forum for Nurses (UK0 - Provide a resource and a voice for lung cancer care in Wales Achievements so far include: - A strong interdisaplinary membemhip of more than 150 professionals wftch has grown year on year. Five succassful conliorences. Publication and cistnbut]on of eight nowstetters Linking and working with the Na'donal Lung Cancer Forum for Nurses (UK) on Identified pnonUes and developments.
J Baker~ G Tapper2. A Wilson ~ IL/andough Hospital, Cardiff, United